US equities
|
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verastem, Inc. - Common Stock
(NQ:
VSTM
)
9.230
+1.520 (+19.71%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
↗
October 14, 2026
Verastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma,...
Via
MarketBeat
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
October 14, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
October 14, 2026
From
Verastem Oncology
Via
Business Wire
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
October 14, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss
↗
May 07, 2026
Via
Chartmill
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
October 02, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
September 28, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
September 24, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
↗
September 21, 2026
Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated...
Via
MarketBeat
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
September 08, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Participate in Upcoming September Investor Conferences
September 02, 2026
From
Verastem Oncology
Via
Business Wire
Verastem (VSTM) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Revenue surged on CO-PACK launch as cash runway extends into late 2027.
Via
The Motley Fool
Topics
Earnings
Verastem Q2 Earnings Call Highlights
↗
August 07, 2026
Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and...
Via
MarketBeat
Topics
Earnings
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
August 06, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
July 28, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
July 22, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Verastem Oncology
Via
Business Wire
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
June 23, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
June 17, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
June 16, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
June 15, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
June 03, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at Jefferies Healthcare Conference
May 27, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
May 12, 2026
From
Verastem Oncology
Via
Business Wire
Verastem Q1 Earnings Call Highlights
↗
May 09, 2026
Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade...
Via
MarketBeat
Topics
Earnings
Verastem (VSTM) Q1 2026 Earnings Transcript
↗
May 08, 2026
Verastem (VSTM) Q1 2026 Earnings Transcript
Via
The Motley Fool
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
May 08, 2026
From
Verastem Oncology
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
